NEOADJUVANT THERAPY OF THE BREAST CANCER WITH HIGH EXPRESSION OF HER-2


如何引用文章

全文:

详细

Patients with regional breast cancer with the high expression or amplification of HER-2 have a very poor prognosis. Before development of modern chemotherapeutic regimens including anthracyclines and taxanes, only 5 % of such patients survived 5 years after treatment. The article presents the analysis of few but well-planned clinical trials, which have shown that adjunction of anti-HER-2 therapy (drug Trastuzumab) to neoadjuvant chemotherapy with anthracyclines and taxanes leads to the increase of full pathomorphologic tumor regression rate from 20 to 40-65 % and reduction of risk of disease progression or death by 40 %.

参考

  1. Hudis C, Modis S. Preoperative chemotherapy for breast cancer: miracle or mirage? JAMA 2007;298:2665-7.
  2. Murhny С. Neoadjuvant therapy for breast cancer. Oncology (suppl.) 2009;23:20-7.
  3. Steger G, Galid A, Gnant M, et. аl. Pathologic complete response with six compared three cycles of neoadjuvant epirubicin plus docetaxel in operable breast cancer results % ABCSG-M. J Clin Oncol 2007;25:2012--8
  4. Von Minckwitz G, Kummel S, Vogel P, et al. Neoadjuvant vinorelbine - capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer phase III randomized Gepar Trio trial. J Natl Cancer Inst 2008;100:542-57.
  5. Gianni L, Baselga J, Eiermann W, et al. Feasibility and tolerability of sequential doxorubicin paclitaxel followed by CMF and its effects on tumor response as preoperative therapy. Clin Cancer Res 2005;11(24):8715-21.
  6. Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase II randomized trial % of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor - positive breast cancer. Cancer 2007;110:244-54.
  7. Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Breast- conserving surgery after preoperative endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor - positive breast cancer. EJC (suppl.) 2010;8:60-1.
  8. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy, results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:3676-85.
  9. Buzdar AU, Valero V, Ibrahim HK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007;13:228-33.
  10. Guarneri V, Rroglio K, Kan S, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006;24:1037-44.
  11. Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment of HER2 overexpressing primary breast cancer with trastuzumab given concomitantly to eptriiblcin/cyclophosphamide followed by docetaxel ± capecitabine. First analysis of efficacy fund safety of the GBG/AGO mutticenter intergroup study GeparOuattro. Presented at: 6th European Breast Cancer Conference; 15-19 April 2008; Berlin, Germany. Abstract 1LB;
  12. Gianni L, Eiemann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastusumab versus neoadjuvant chemotherapy alone, in patients with HER2 - positive locally advanced breast cancer (the NOAH trial): a randomized controlled superiority trial with a parallel HER - negative cohort. Lancet 2010;375:377-84.
  13. Semiglazov V, Eiermann W, Manikhas A, et al. Surgical aspects of the NOAH phase III trial (neoadjuvant trastusumab (Herceptin) in HER 2 - positive locally advanced breast cancer). Eur J Cancer 2008;6(75):115.
  14. Hayes DF, Thor AD, Dressier LG, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007;357(15):1496-506.
  15. Rouzier R, Perou CM, Symanns WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11(16):5673-85.
  16. Limentani SA, Brufsky AM, Erban JK, et al. Phase II study of neoadjuvant docetaxei, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin pfus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. J Clin Oncol 2007;25:1232-8.
  17. Hurley J, Doliny P, Reis I, et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Ciin Oncol 2006;24:1831-8.
  18. Coudert BP, Largillier R, Amould L, et al. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor recepior-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol 2007;25:2678-84.
  19. Wenzel C, Hussian D, Bartsch R, et al. Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study. J Cancer Res Clin Oncol 2004;130:400-4.
  20. Burstein HJ, Harris LN, German R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Qncol 2003;21:46-53.
  21. Sanchez-Munoz A, Garcia-Tapiador AM, Duenas-Garcia RE, et al. Safety and efficacy of neoadjuvant sequential cose-dense chemotherapy doublets combined with trastuzumab in patients with HER-2-positive early stage breast cancer. Breast J 2008;14(6):506-7.
  22. Peintinger F, Buzdar AU, Kuerer HM, et al. Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol 2008;19(12):2020-5.
  23. Gluck S, McKenna EF Jr, Royce M. XeNA: capecitabine plus docetaxel, with or without trastuzumab, as preoperative therapy for early breast cancer. Int J Med Sci 2008;5(6):341-6
  24. Chang HR, Slamon D, Prati R, et al. A phase II study of neoadjuvant docetaxel/carboplatin or without trastusumab in locally advanced breast cancer: response and cardiotoxicity. J Clin Oncol (ASCO Annual Meeting Proceedings, Post-Meeting Edition) 2006;24(18):A10515.
  25. Snoj N, Bedard PL, de Azambuja E, et al. Are we HER- ting for innovation in neoadjuvant breast cancer trial design? Breast Cancer Res 2009;11(1):201.
  26. Tan-Chiu E, Yothers G, Romond E et.al. Assessment of cardiac dysfunction in a randomized trial companing doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:7811-9.
  27. Perez EA, Suman VJ, Davidson NE, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cencer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008;26(8):1231-8.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2010
##common.cookie##